Last Updated : August 19, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
danicopan (Voydeya)
Therapeutic Area: Paroxysmal nocturnal hemoglobinuria (PNH)
Draft recommendations posted for stakeholder feedback: September 19, 2024
End of feedback period: October 4, 2024
Draft Recommendation
eplontersen (Wainua)
Therapeutic Area: Polyneuropathy in hereditary transthyretin-mediated amyloidosis
Draft recommendations posted for stakeholder feedback: September 19, 2024
End of feedback period: October 4, 2024
Draft Recommendation
clindamycin plus benzoyl peroxide and adapalene (Cabtreo)
Therapeutic Area: acne vulgaris
Draft recommendations posted for stakeholder feedback: September 19, 2024
End of feedback period: October 4, 2024
Draft Recommendation
elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta)
Therapeutic Area: Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older
Draft recommendations posted for stakeholder feedback: September 19, 2024
End of feedback period: October 4, 2024
Draft Recommendation
pembrolizumab (Keytruda)
Therapeutic Area: Gastric or gastroesophageal junction (GEJ) adenocarcinoma
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
ivosidenib (Tibsovo)
Therapeutic Area: Acute myeloid leukemia (AML)
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
abemaciclib (Verzenio)
Therapeutic Area: Adjuvant treatment of HR-positive, HER2-negative early breast cancer
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
osimertinib (Tagrisso)
Therapeutic Area: Non-small cell lung cancer
Draft recommendations posted for stakeholder feedback: September 5, 2024
End of feedback period: September 19, 2024
Draft Recommendation
Open Calls for Patient and Clinician Input
Therapeutic Area
Therapeutic Area:
Endometrial cancer that is mismatch repair deficient (dMMR)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Endometrial cancer that is mismatch repair proficient (pMMR).
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Reduce the risk of major adverse cardiovascular events
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
paroxysmal nocturnal hemoglobinuria (PNH)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Multiple myeloma, eligible for autologous stem cell transplant
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Acromegaly, adults
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Rett syndrome (RTT)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Friedrich’s ataxia
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Previously treated multiple myeloma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Previously treated multiple myeloma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Last Updated : August 19, 2024